Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility
Abstract Background The methylenetetrahydrofolate reductase (MTHFR) rs1801131 A/C variant results in a decrease in MTHFR enzymatic activity, which may play an important role in folate metabolism and is also an important source of DNA methylation and DNA synthesis. Several case-control studies have b...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-04-01
|
| Series: | Hereditas |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41065-020-00129-x |
| _version_ | 1818274434582052864 |
|---|---|
| author | Shuaili Xu Li Zuo |
| author_facet | Shuaili Xu Li Zuo |
| author_sort | Shuaili Xu |
| collection | DOAJ |
| description | Abstract Background The methylenetetrahydrofolate reductase (MTHFR) rs1801131 A/C variant results in a decrease in MTHFR enzymatic activity, which may play an important role in folate metabolism and is also an important source of DNA methylation and DNA synthesis. Several case-control studies have been conducted to assess the association of MTHFR rs1801131 polymorphism with the risk of urinary cancers, yet with conflicting conclusions. To derive a more precise estimation of above relationship, the association between the MTHFR rs1801131 A/C polymorphism and the risk of urinary cancer was performed. Methods A total of 28 case-control studies was identified. The odds ratios (OR) with 95% confidence intervals (CI) was calculated to assess. Results On one hand, we found that the MTHFR rs1801131 A/C polymorphism was associated with increased whole urinary cancers’ risk (for example CA vs. AA: OR = 1.12. 95%CI = 1.01–1.24). On the other hand, we found that the MTHFR rs1801131 A/C polymorphism might increase bladder cancer risk both in Asian (C-allele vs. A-allele: OR = 1.35. 95%CI = 1.15–1.60) and African populations (CA vs. AA: OR = 1.63. 95%CI = 1.17–2.25). Conclusions Our current analysis suggested that MTHFR rs1801131 A/C is associated with urinary cancers, especially bladder cancer. |
| first_indexed | 2024-12-12T22:13:48Z |
| format | Article |
| id | doaj.art-a50787d9af104cb597abf577c6433aa4 |
| institution | Directory Open Access Journal |
| issn | 1601-5223 |
| language | English |
| last_indexed | 2024-12-12T22:13:48Z |
| publishDate | 2020-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Hereditas |
| spelling | doaj.art-a50787d9af104cb597abf577c6433aa42022-12-22T00:10:09ZengBMCHereditas1601-52232020-04-01157111510.1186/s41065-020-00129-xAssociation between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibilityShuaili Xu0Li Zuo1Department of Paediatrics, Changzhou No. 2 People’s Hospital Affiliated to Nanjing Medical UniversityDepartment of Urology, Changzhou No. 2 People’s Hospital Affiliated to Nanjing Medical UniversityAbstract Background The methylenetetrahydrofolate reductase (MTHFR) rs1801131 A/C variant results in a decrease in MTHFR enzymatic activity, which may play an important role in folate metabolism and is also an important source of DNA methylation and DNA synthesis. Several case-control studies have been conducted to assess the association of MTHFR rs1801131 polymorphism with the risk of urinary cancers, yet with conflicting conclusions. To derive a more precise estimation of above relationship, the association between the MTHFR rs1801131 A/C polymorphism and the risk of urinary cancer was performed. Methods A total of 28 case-control studies was identified. The odds ratios (OR) with 95% confidence intervals (CI) was calculated to assess. Results On one hand, we found that the MTHFR rs1801131 A/C polymorphism was associated with increased whole urinary cancers’ risk (for example CA vs. AA: OR = 1.12. 95%CI = 1.01–1.24). On the other hand, we found that the MTHFR rs1801131 A/C polymorphism might increase bladder cancer risk both in Asian (C-allele vs. A-allele: OR = 1.35. 95%CI = 1.15–1.60) and African populations (CA vs. AA: OR = 1.63. 95%CI = 1.17–2.25). Conclusions Our current analysis suggested that MTHFR rs1801131 A/C is associated with urinary cancers, especially bladder cancer.http://link.springer.com/article/10.1186/s41065-020-00129-xMTHFRrs1801131ProstateBladderRenalPolymorphism |
| spellingShingle | Shuaili Xu Li Zuo Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility Hereditas MTHFR rs1801131 Prostate Bladder Renal Polymorphism |
| title | Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility |
| title_full | Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility |
| title_fullStr | Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility |
| title_full_unstemmed | Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility |
| title_short | Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility |
| title_sort | association between methylenetetrahydrofolate reductase gene rs1801131 a c polymorphism and urinary tumors susceptibility |
| topic | MTHFR rs1801131 Prostate Bladder Renal Polymorphism |
| url | http://link.springer.com/article/10.1186/s41065-020-00129-x |
| work_keys_str_mv | AT shuailixu associationbetweenmethylenetetrahydrofolatereductasegeners1801131acpolymorphismandurinarytumorssusceptibility AT lizuo associationbetweenmethylenetetrahydrofolatereductasegeners1801131acpolymorphismandurinarytumorssusceptibility |